- Ethical Approval and Consent to participate: The experimental protocol was established, according to the ethical guidelines of the Helsinki Declaration and was approved by the Human Ethics Committee of Xiangyang First People’s Hospital affiliated to Hubei Medical University (Issue No. S109 [2016]). Written informed consent was obtained from individual or guardian participants.
- Consent for publication: Not applicable.
- Availability of data and materials: All data generated or analysed during this study are included in this published article.
- Competing interests: The authors declare no conflicts of interest.
- Funding: This work was supported by grants from Xiangyang science and Technology Bureau:Development of movable head mounted oxygen supply and isolation system for patients with COVID-19 pneumonia (2020ZD01, PENG AN); 2021 science and technology innovation project of Xiangyang NO.1 People's Hospital: Research on risk stratication decision and key problems of prostate cancer based on in-depth learning of MRI/ultrasound imaging omics(XYY2021Q16, PENG AN).
- Authors' contributions: Peng An conceived and drafted the manuscript. All of the authors contributed to the literature review, revised the manuscript critically for important intellectual content, AN approved the final version to be published and agreed to act as guarantors of the work.
- Acknowledgements: I am very grateful to Mr. Zhu Yong for his guidance and the statistical methods provided in his article15.The authors gratefully acknowledge Weiping Gu and Anna Gong for assistance with translating references.The study was funded by the Agency for Integrated Care, Red Cross and Development Board and Ministry of Hubei Health. The authors would like to thank the anatomists for taking time to participate in the research study and for generously sharing their experiences and medical informations.
- Authors' information: PENG AN Department of Radiology, Xiangyang No. 1 People's Hospital Affiliated to Hubei University of Medicine. Hubei ,441000,China. The Affiliated Hospital of Nanjing University of Chinese Medicine,Jiangsu Province Hospital of Chinese medicine,The First Clinical Medical College, 155 Hanzhong Road, Nanjing 210029, Jiangsu Province, China.
References and Notes
1.Naji O, Daemen A, Smith A, et al. Does the presence of a cesarean section scar influence the site of placental implantation and subsequent migration in future pregnancies: a prospective case-control study. Ultrasound Obstet Gynecol. 2012;40(5):557-561. doi:10.1002/uog.11133.
2.Timor-Tritsch IE, Monteagudo A, Cali G, et al. Cesarean scar pregnancy and early placenta accreta share common histology. Ultrasound Obstet Gynecol. 2014;43(4):383-395. doi:10.1002/uog.13282.
3.Silver RM, Barbour KD. Placenta accreta spectrum: accreta, increta, and percreta. Obstet Gynecol Clin North Am. 2015;42(2):381-402. doi:10.1016/j.ogc.2015.01.014.
4.Marcellin L, Delorme P, Bonnet MP, et al. Placenta percreta is associated with more frequent severe maternal morbidity than placenta accreta. Am J Obstet Gynecol. 2018;219(2):193.e1-193.e9. doi:10.1016/j.ajog.2018.04.049.
5.Silver RM. Abnormal Placentation: Placenta Previa, Vasa Previa, and Placenta Accreta. Obstet Gynecol. 2015;126(3):654-668. doi:10.1097/AOG.0000000000001005.
6.di Pasquo E, Ghi T, Calì G, et al. Intracervical lakes as sonographic marker of placenta accreta spectrum disorder in patients with placenta previa or low-lying placenta. Ultrasound Obstet Gynecol. 2020;55(4):460-466. doi:10.1002/uog.21866.
7.Jauniaux E, Collins S, Burton GJ. Placenta accreta spectrum: pathophysiology and evidence-based anatomy for prenatal ultrasound imaging. Am J Obstet Gynecol. 2018;218(1):75-87. doi:10.1016/j.ajog.2017.05.067.
8.Timor-Tritsch IE, Monteagudo A, Cali G, et al. Cesarean scar pregnancy is a precursor of morbidly adherent placenta. Ultrasound Obstet Gynecol. 2014;44(3):346-353. doi:10.1002/uog.13426.
9.Chen X, Shan R, Song Q, Wei X, Liu W, Wang G. Placenta percreta evaluated by MRI: correlation with maternal morbidity. Arch Gynecol Obstet. 2020;301(3):851-857. doi:10.1007/s00404-019-05420-5.
10.Berkley EM, Abuhamad A. Imaging of Placenta Accreta Spectrum. Clin Obstet Gynecol. 2018;61(4):755-765. doi:10.1097/GRF.0000000000000407.
11.Jauniaux E, Dimitrova I, Kenyon N, et al. Impact of placenta previa with placenta accreta spectrum disorder on fetal growth. Ultrasound Obstet Gynecol. 2019;54(5):643-649. doi:10.1002/uog.20244.
12.Society of Gynecologic Oncology; American College of Obstetricians and Gynecologists and the Society for Maternal–Fetal Medicine, Cahill AG, et al. Placenta Accreta Spectrum. Am J Obstet Gynecol. 2018;219(6):B2-B16. doi:10.1016/j.ajog.2018.09.042.
13.Bartels HC, Postle JD, Downey P, Brennan DJ. Placenta Accreta Spectrum: A Review of Pathology, Molecular Biology, and Biomarkers. Dis Markers. 2018;2018:1507674. Published 2018 Jul 3. doi:10.1155/2018/1507674.
14.Sawada, M., Matsuzaki, S., Mimura, K., Kumasawa, K., Endo, M., & Kimura, T. 2016. Successful conservative management of placenta percreta: Investigation by serial magnetic resonance imaging of the clinical course and a literature review. The journal of obstetrics and gynaecology research, 4212, pp.1858–1863.
15.Zhu Y, Mao Y, Chen J, et al. Radiomics-based model for predicting early recurrence of intrahepatic mass-forming cholangiocarcinoma after curative tumor resection. Sci Rep. 2021;11(1):18347. Published 2021 Sep 15. doi:10.1038/s41598-021-97796-1.
16.Duzyj CM, Cooper A, Mhatre M, et al. Placenta Accreta: A Spectrum of Predictable Risk, Diagnosis, and Morbidity. Am J Perinatol. 2019;36(10):1031-1038. doi:10.1055/s-0038-1676111.
17.Di Mascio D, Calì G, D'antonio F. Updates on the management of placenta accreta spectrum. Minerva Ginecol. 2019;71(2):113-120. doi:10.23736/S0026-4784.18.04333-2.
18.Jauniaux E, Hussein AM, Zosmer N, et al. A new methodologic approach for clinico-pathologic correlations in invasive placenta previa accreta. Am J Obstet Gynecol. 2020;222(4):379.e1-379.e11. doi:10.1016/j.ajog.2019.11.1246.
19.Piñas Carrillo A, Chandraharan E. Placenta accreta spectrum: Risk factors, diagnosis and management with special reference to the Triple P procedure. Womens Health (Lond). 2019;15:1745506519878081. doi:10.1177/1745506519878081.
20.Matsuzaki S, Yoshino K, Endo M, et al. Successful anticoagulant therapy for disseminated intravascular coagulation during conservative management of placenta percreta: a case report and literature review. BMC Pregnancy Childbirth. 2017;17(1):443. Published 2017 Dec 29. doi:10.1186/s12884-017-1634-8.
21.Cali G, Forlani F, Foti F, et al. Diagnostic accuracy of first-trimester ultrasound in detecting abnormally invasive placenta in high-risk women with placenta previa. Ultrasound Obstet Gynecol. 2018;52(2):258-264. doi:10.1002/uog.19045.
22.Cui R, Li M, Lu J, Bai H, Zhang Z. Management strategies for patients with placenta accreta spectrum disorders who underwent pregnancy termination in the second trimester: a retrospective study. BMC Pregnancy Childbirth. 2018;18(1):298. Published 2018 Jul 11. doi:10.1186/s12884-018-1935-6.
23.Hobson SR, Kingdom JC, Murji A, et al. No. 383-Screening, Diagnosis, and Management of Placenta Accreta Spectrum Disorders. J Obstet Gynaecol Can. 2019;41(7):1035-1049. doi:10.1016/j.jogc.2018.12.004.
24.Kaelin Agten A, Cali G, Monteagudo A, Oviedo J, Ramos J, Timor-Tritsch I. The clinical outcome of cesarean scar pregnancies implanted "on the scar" versus "in the niche". Am J Obstet Gynecol. 2017;216(5):510.e1-510.e6. doi:10.1016/j.ajog.2017.01.019.
25.Thiravit S, Lapatikarn S, Muangsomboon K, Suvannarerg V, Thiravit P, Korpraphong P. MRI of placenta percreta: differentiation from other entities of placental adhesive disorder. Radiol Med. 2017;122(1):61-68. doi:10.1007/s11547-016-0689-3.
26.Kilcoyne A, Shenoy-Bhangle AS, Roberts DJ, Sisodia RC, Gervais DA, Lee SI. MRI of Placenta Accreta, Placenta Increta, and Placenta Percreta: Pearls and Pitfalls. AJR Am J Roentgenol. 2017;208(1):214-221. doi:10.2214/AJR.16.16281.
27.Chen X, Shan R, Song Q, Wei X, Liu W, Wang G. Placenta percreta evaluated by MRI: correlation with maternal morbidity. Arch Gynecol Obstet. 2020;301(3):851-857. doi:10.1007/s00404-019-05420-5.